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Bone Resorption Inhibitor Alendronate Normalizes the Reduced Bone
Thickness of TRPV5−/− Mice
Tom Nijenhuis,1 Bram CJ van der Eerden,2 Joost GJ Hoenderop,1 Harrie Weinans,3 Johannes PTM van Leeuwen,2 and
René JM Bindels1
ABSTRACT: TRPV5 is a Ca2+-selective channel involved in transcellular Ca2+ absorption expressed in kidney
and in the ruffled border of osteoclasts. Studies in hypercalciuric TRPV5 knockout (TRPV5−/−) mice, which
display significantly increased vitamin D levels, showed that TRPV5 ablation increases number and size of
osteoclasts but impairs osteoclast-mediated bone resorption. The latter is not in line with the observed
decreased bone thickness in TRPV5−/− mice. Bisphosphonates also inhibit osteoclast-mediated bone resorp-
tion. The aim of this study was to evaluate the effect of alendronate on the expression of the Ca2+ transporters
in bone, kidney, and duodenum and, importantly, the bone phenotype in TRPV5−/− mice. Wildtype (TRPV5+/+)
and TRPV5−/− mice were treated during 10 wk with 2 mg/kg alendronate or vehicle weekly and housed in
metabolic cages at the end of treatment. Urine and blood samples were taken for biochemical analysis, and
duodenum, kidney, and femur were sampled. Expression of Ca2+ transporters and osteoclast ruffled border
transporters in bone and cultured osteoclasts was determined by QPCR analysis. Femurs were scanned using
CT, and resorption pit assays were performed in bone marrow cultures isolated from TRPV5+/+ and
TRPV5−/− mice. Alendronate treatment enhanced bone thickness in TRPV5+/+ mice but also normalized the
disturbed bone morphometry parameters in TRPV5−/− mice. Bone TRPV5 expression was specifically
enhanced by alendronate, whereas the expression of Ca2+ transporters in kidney and intestine was not
altered. The expression of the osteoclast ruffled border membrane proteins chloride channel 7 (CLC-7) and
the vacuolar H+-ATPase did not differ between both genotypes, but alendronate significantly enhanced the
expression and PTH levels in TRPV5−/− mice. The expression of TRPV5, CLC-7, and H+-ATPase in
osteoclast cultures was not affected by alendronate. The number of resorption pits was reduced in TRPV5−/−
bone marrow cultures, but the response to vitamin D was similar to that in TRPV5+/+ cultures. The alen-
dronate-induced upregulation of TRPV5 in bone together with the decreased resorptive capacity of
TRPV5−/− osteoclasts in vitro suggests that TRPV5 has an important role in osteoclast function. However,
our data indicate that significant bone resorption still occurs in TRPV5−/− mice, because alendronate treat-
ment normalized bone thickness in these mice. Thus, TRPV5−/− mice are able to rescue the resulting defect
in osteoclast-mediated bone resorption, possibly mediated by the long-term hypervitaminosis D or other
(non)hormonal compensatory mechanisms.
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INTRODUCTION
PLASMA CA2+ CONCENTRATION is kept within narrow lim-its by tight regulation of intestinal Ca2+ absorption, re-
nal Ca2+ reabsorption, and exchange of Ca2+ from bone.(1,2)
The active form of vitamin D, 1,25-dihydroxyvitamin D3
[1,25(OH)2D3], and PTH are the main calcitropic hor-
mones known to be involved in the maintenance of verte-
brate Ca2+ homeostasis.(1) 1,25(OH)2D3- and PTH-
stimulated transcellular Ca2+ (re)absorption in kidney and
intestine involves Ca2+ entry across the luminal membrane
through the epithelial Ca2+ channels TRPV5 and TRPV6,
respectively.(2) The majority of the body Ca2+ content is,
thereafter, stored in bone, where the balanced processes of
bone formation and resorption maintain bone homeosta-
sis.(3) The expression of TRPV5 and TRPV6 in bone was
previously shown, but their physiological roles remained
elusive.(4) TRPV5 knockout (TRPV5−/−) mice displayed a
profound renal Ca2+ wasting and showed a bone phenotype
characterized by reduced bone thickness.(5) Interestingly,
TRPV5 ablation was recently shown to result in increased
numbers and size of osteoclasts, whereas osteoclast bone
resorptive capacity in tibial bone marrow cultures from
TRPV5−/− mice was severely decreased.(6) These data sug-
gested that TRPV5 is involved in osteoclast-mediated bone
resorption. However, the impaired osteoclast activity seemsThe authors state that they have no conflicts of interest.
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at variance with the observed bone phenotype in TRPV5−/−
mice.
TRPV5 is a highly Ca2+-selective ion channel localized at
the luminal membrane of the late distal convoluted tubule
(DCT) and connecting tubule (CNT) in kidney, where trans-
cellular Ca2+ reabsorption takes place.(1,2,7) TRPV6 is the
homologous epithelial Ca2+ channel localized along the
brush-border membrane of duodenum.(1,2,8) After Ca2+ en-
try across the luminal membrane in kidney or intestine,
Ca2+ is bound to Ca2+-binding proteins (calbindins), and
this complex either diffuses or, alternatively, is translocated
by vesicular transport to the basolateral membrane. There-
after, Ca2+ is extruded to the blood compartment by the
Na+/Ca2+ exchanger (NCX1) and/or the plasma membrane
Ca2+-ATPase (PMCA1b).(1,2,7)
It was recently shown that the phenotype of calbindin-
D28K and calbindin-D9K knockout mice is rather mild, par-
ticularly because of compensatory upregulation of the ex-
pression of other Ca2+-transporting proteins involved in
Ca2+ (re)absorption, partly induced by hormonal counter-
regulation.(9–11) In contrast, TRPV5−/− mice showed a clear
phenotype characterized by profound renal Ca2+ wasting
caused by impaired active Ca2+ reabsorption in DCT and
CNT, accompanied by reduced expression of the down-
stream Ca2+ transporters.(5,12) To further study the signifi-
cance of TRPV5, we showed that, when Ca2+ entry through
TRPV5 in polarized monolayers of rabbit CNT/CCD is
blocked with the potent inhibitor ruthenium red, this elimi-
nated PTH-stimulated transepithelial Ca2+ transport and
simultaneously decreased the expression of calbindin-D28K
and the basolateral NCX1, whereas TRPV5 expression re-
mained unaffected.(13) Together, these data underline the
importance of TRPV5 as the gatekeeper in renal active
Ca2+ reabsorption and show that the Ca2+ influx through
TRPV5 controls the expression of the downstream Ca2+
transport proteins. In addition, a significant hypervitamin-
osis D was present in TRPV5−/− mice, along with increased
intestinal Ca2+ absorption. Furthermore, the hypervitamin-
osis D is responsible for the intestinal hyperabsorption of
Ca2+ through upregulation of the intestinal Ca2+ transport
proteins TRPV6 and calbindin-D9K.
(14)
Previously, we showed that, in bone, TRPV5 localizes
exclusively to the ruffled border of osteoclasts.(6) Further-
more, calbindin-D9K, calbindin-D28K, NCX1, and PMCA1b
were shown to be present in these bone cells.(6) Together
with the near absence of resorption pit formation by
TRPV5−/− osteoclasts, these data suggested that the trans-
cellular Ca2+ transport machinery, and TRPV5 in particu-
lar, is essential for proper osteoclastic bone resorption.(6)
The balance of bone formation and resorption can be
clinically influenced by the administration of bisphospho-
nates, which are used in the treatment of malignancy-
related hypercalcemia and osteolytic bone disease, primary
and secondary hyperparathyroidism, Paget’s disease of
bone, and osteoporosis.(15,16) Because bisphosphonates are
potent inhibitors of osteoclast-mediated bone resorption,
the action of these compounds in wildtype (TRPV5+/+) and
TRPV5−/− mice, as well as the effects on the expression of
TRPV5 and TRPV6, may add to our knowledge of the
physiological role(s) of these epithelial Ca2+ channels in
bone homeostasis.(16) Furthermore, the effect of bisphos-
phonate treatment on renal and duodenal Ca2+ (re)absorp-
tion has not been evaluated in detail.
The aim of this study was, therefore, to determine the in
vivo effect of the bisphosphonate alendronate on Ca2+ and
bone homeostasis. The expression of the Ca2+ transport
proteins in bone, kidney, and intestine was determined by
real-time QPCR analysis and/or semiquantitative immuno-
histochemistry. The action of alendronate on bone mor-
phology in TRPV5+/+ mice and, importantly, the bone phe-
notype in TRPV5−/− mice, was evaluated by CT.
MATERIALS AND METHODS
Alendronate treatment in TRPV5+/+ (wildtype) and
TRPV5−/− mice
TRPV5−/− mice were generated by targeted ablation of
the TRPV5 gene.(5) TRPV5+/+ mice and TRPV5−/− litter-
mates were housed in a light- and temperature-controlled
room with ad libitum access to deionized drinking water
and standard pelleted chow (0.25% [wt/vol] Na; 1.1% [wt/
vol] Ca). Eight-week-old TRPV5+/+ and TRPV5−/− mice
were treated for 10 wk with 2 mg/kg alendronate (3-amino-
1-hydroxypropylidene-1,1-bisphosphonate; n  9) or ve-
hicle (n 9) once weekly by subcutaneous injection. At the
end of the treatment period, the animals were housed in
metabolic cages enabling ration feeding and collection of
24-h urine samples under mineral oil, preventing evapora-
tion. After termination of the metabolic experiments, blood
samples were taken, and the animals were anesthetized and
killed by cervical dislocation. Immediately thereafter, duo-
denum, kidney, and femur were sampled. Kidney cortex
was immediately frozen in liquid nitrogen and, in addition,
renal tissue was fixated for immunohistochemistry by im-
mersion in 1% (wt/vol) periodate-lysine-paraformaldehyde
(PLP) for 2 h and 15% (wt/vol) sucrose in PBS overnight.
Subsequently, kidney and duodenum samples were stored
at –80°C until further processing. The animal ethics board
of the Radboud University Nijmegen approved all animal
studies.
Analytical procedures
Serum and urine Ca2+ concentrations were determined
using a colorimetric assay as described previously.(17)
Na+ and Li+ concentrations were determined flame-
spectrophotometrically (Eppendorf FCM 6343),(12) and
urine pH was measured using an electronic ion analyzer
(Hanna Instruments, Szeged, Hungary). In addition, deoxy-
pyridinoline (DPD) was analyzed in urine (Biometra, San
Francisco, CA, USA). Serum 1,25(OH)2D3 levels were de-
termined with an [125I]1,25(OH)2D3 radioimmunoassay
(IDS, Fountain Hills, AZ, USA) and serum PTH using an
immunoradiometric assay (Immutopics, San Clemente,
CA, USA).
Real-time QPCR analysis
Total RNA was extracted from bone, kidney, and duo-
denum using TriZol Total RNA Isolation Reagent (Gibco
BRL, Breda, The Netherlands). Femurs, from which the
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bone marrow was removed by flushing with PBS, were first
homogenized using a Mikro Dismembrator S (Sartorius,
Goettingen, Germany). The obtained RNA was subjected
to DNase treatment and reverse transcribed.(4) Subse-
quently, the cDNA was used to measure TRPV5 and
TRPV6 mRNA in bone by real-time QPCR as described
previously.(18) In addition, the mRNA levels of the vacuolar
H+-ATPase and the Cl− channel ClC-7, which are present
in the ruffled border membrane of osteoclasts and involved
in bone resorption, were determined.(19–22) Vacuolar
H+-ATPase primer sequences were 5-TCAGATCCTA-
AGCCGAAGTTGAG-3 and 5-GACCAAGGCCAC-
CTCTTCAC-3, and 5-TCCACCTGGGATCATGGGC-
TCTATGT-3 for the probe. In the case of ClC-7, these
were 5-CCTGTGGTGGAGGATGTAGGA-3, 5-
TCTCCACAAACACCTTATGCTTCA-3, and 5-
TCCAAGGCTTGATCCTGCGTTCCC-3, respectively.
Furthermore, TRPV5 and calbindin-D28K mRNA expres-
sion in kidney and TRPV6 and calbindin-D9K mRNA levels
in duodenum were determined.(14,23) The mRNA expres-
sion level of the housekeeping gene hypoxanthine-guanine
phosphoribosyl transferase (HPRT) was used as an endog-
enous control, which enabled calculation of specific mRNA
expression levels as a ratio of HPRT.
Immunohistochemistry
Staining of kidney sections for TRPV5 and calbindin-
D28K was performed on cryosections of PLP-fixed kidney
samples as described previously.(7,17) For semiquantitative
determination of protein abundance, images were made us-
ing a Zeiss fluorescence microscope equipped with a digital
camera (Nikon DXM1200). Images were analyzed with the
Image Pro Plus 4.1 image analysis software (Media Cyber-
netics, Silver Spring, MD, USA), resulting in quantification
of the protein levels as the mean of integrated optical den-
sity (IOD).
Bone analysis
To evaluate the effect of alendronate on the bone phe-
notype in TRPV5−/− mice and the possible correlation be-
tween TRPV5 and TRPV6 expression and bone homeosta-
sis, femurs from control and alendronate-treated TRPV5+/+
and TRPV5−/− mice were scanned using the SkyScan 1072
microtomograph (SkyScan, Antwerp, Belgium). Scans were
processed and a 3D morphometric analysis of the bone
was performed using the 3D-Calculator project free soft-
ware (http://www.eur.nl/fgg/orthopaedics) followed by ad-
ditional analyses, using software available on http://www.
skyscan.be/next/downloads.html. Measured parameters
were expressed according to bone histomorphometry no-
menclature.(24)
Murine bone marrow cultures and resorption
pit assay
Murine bone marrow cultures were performed as de-
scribed previously.(6) In short, different 1,25(OH)2D3 con-
centrations were applied to bone marrow cultures for 6
days to study the effect of 1,25(OH)2D3 on bone resorption
by TRPV5+/+ and TRPV5−/− osteoclasts. Thereafter, mu-
rine osteoclasts cultured on bovine cortical bone slices were
lysed in water for Coomassie brilliant blue staining of re-
sorption pits. Bovine cortical bone slices were sonicated in
10% (vol/vol) ammonia (Merck) for 10 min. After exten-
sive washing, the cells were incubated in filtered potassium
aluminum sulfate (Sigma) for 10 min and subsequently
stained with filtered Coomassie brilliant blue (Phastgel
Blue R; Amersham Pharmacia Biotech) for 5 s. The resorp-
tion pits were analyzed with BIOQUANT software (Bio-
quant, Nashville, TN, USA). In addition, we determined
the effect of alendronate on the expression of TRPV5, the
chloride channel CLC-7, and the vacuolar H+-ATPase in
cultured osteoclasts by real-time QPCR analysis as de-
scribed above. To this end, alendronate was applied to the
osteoclasts for 24 h at a concentration of 10−5 M, after
which RNA was extracted.
Statistical analysis
Data are expressed as means ± SE. Statistical compari-
sons were analyzed by one-way ANOVA and Fisher’s mul-
tiple comparison; p < 0.05 was considered statistically sig-
nificant. All analyses were performed using the StatView
Statistical Package software (Power PC version 4.51) on an
Apple iMac computer.
RESULTS
Metabolic studies in alendronate-treated TRPV5+/+
and TRPV5−/− mice
TRPV5+/+ and TRPV5−/− mice were treated for 10 wk
with 2 mg/kg alendronate or vehicle by weekly subcutane-
ous injections. The obtained metabolic data are shown in
Table 1. Genetic ablation of TRPV5 resulted in an ∼10-fold
increase in Ca2+ excretion compared with TRPV5+/+ mice,
an enhanced urine volume, and slightly elevated serum
Ca2+ levels. Alendronate treatment significantly decreased
Ca2+ excretion in TRPV5−/− mice, but calciuresis remained
unaltered in TRPV5+/+ mice. Likewise, alendronate re-
duced the increased diuresis in TRPV5−/− mice but not in
TRPV5+/+ mice. Serum Ca2+ levels, Na+ excretion, Li+
clearance, and urine pH were not affected by alendronate
treatment. TRPV5−/− mice showed a significantly increased
serum 1,25(OH)2D3 concentration. Alendronate treat-
ment did not affect serum 1,25(OH)2D3 levels in TRPV5
+/+
mice. TRPV5 ablation significantly increased serum
1,25(OH)2D3 levels, whereas alendronate normalized se-
rum 1,25(OH)2D3 in these TRPV5
−/− mice. Serum PTH
levels were not altered in TRPV5−/− mice and alendronate-
treated TRPV5+/+ mice. Interestingly, alendronate mark-
edly increased serum PTH levels in TRPV5−/− mice com-
pared with untreated TRPV5−/− and TRPV5+/+ mice. Urine
DPD levels were significantly reduced in TRPV5−/− mice
compared with untreated controls.
Bone analysis
To evaluate the effect of alendronate on bone morphol-
ogy in TRPV5+/+ and TRPV5−/− mice, femurs were scanned
using CT. Detailed 3D morphometric analysis showed
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that trabecular thickness (Tb.Th), cortical thickness
(Ct.Th), cortical volume (Ct.V.), and cortical bone volume
fraction (Ct.V/Dp.V) were decreased in TRPV5−/− mice
(Table 2). Treatment with alendronate increased the tra-
becular bone volume fraction (BV/TV), Ct.Th, and Ct.V/
Dp.V in TRPV5+/+ mice, confirming the therapeutic effi-
cacy of this bone resorption inhibitor. Interestingly,
alendronate increased Tb.Th, BV/TV, Ct.Th, Ct.V, and
Ct.V/Dp.V. in TRPV5−/− mice to levels that did not differ
from untreated TRPV5+/+ mice, showing that alendronate
was able to normalize the bone morphology parameters in
these mice.
mRNA expression of TRPV5 and osteoclast
markers in bone and cultured osteoclasts
Bone TRPV5 mRNA levels in femur, as determined by
real-time QPCR analysis, were significantly enhanced by
alendronate in TRPV5+/+ mice (Fig. 1A). In contrast, bone
TRPV6 mRNA levels were unaffected by alendronate
treatment (Fig. 1B). TRPV5 gene ablation did not alter the
TRPV6 mRNA levels in femur. To further evaluate the
effect of alendronate on osteoclasts, bone mRNA expres-
sion levels of the vacuolar H+-ATPase and the chloride
channel ClC-7 were determined, which both are expressed
at the ruffled border of the osteoclast and are involved in
the acidification of resorption pits as part of the process of
bone resorption.(19,20) The vacuolar H+-ATPase (Fig. 2A)
and ClC-7 mRNA expression (Fig. 2B) was not altered by
TRPV5 ablation. Furthermore, alendronate treatment did
not alter the expression of these osteoclast markers in
TRPV5+/+ mice. In TRPV5−/− mice, however, alendronate
significantly enhanced the bone vacuolar H+-ATPase and
ClC-7 mRNA expression levels. To ascertain whether the
above-described transcriptional regulation was the result of
a direct effect of alendronate on the osteoclast, we deter-
mined the expression of these transport proteins in cultured
osteoclasts treated with alendronate. In contrast to the
alendronate-induced TRPV5 upregulation in bone, TRPV5
mRNA expression in cultured osteoclasts was not altered
by alendronate application (Fig. 3A). Likewise, the expres-
sion of the chloride channel CLC-7 (Fig. 3B) and the vacu-
olar H+-ATPase (Fig. 3C) was unaltered by alendronate.
Renal and duodenal expression of Ca2+ transporters
Alendronate administration did not change renal TRPV5
mRNA (Fig. 4A) or protein expression (Figs. 5A and 5C) in
TRPV5+/+ mice as determined by real-time QPCR and
semiquantitative immunohistochemistry, respectively.
TRPV5−/− mice showed significantly decreased renal cal-
bindin-D28K mRNA (Fig. 4B) and protein expression in
DCT and CNT (Figs. 5B and 5D). However, calbindin-
D28K mRNA (Fig. 4B) and protein abundance (Figs. 5B
and 5D) in both genotypes were not affected by alendro-
nate. TRPV5 ablation resulted in a significantly enhanced
intestinal mRNA expression of the Ca2+ transporters
TRPV6 (Fig. 6A) and calbindin-D9K (Fig. 6B). In both
TRPV5+/+ and TRPV5−/− mice, duodenal TRPV6 and cal-
bindin-D9K mRNA levels were not altered by alendronate
treatment.
Murine bone marrow cultures and resorption
pit assay
When bone marrow from TRPV5+/+ and TRPV5−/− mice
was cultured in the presence of FCS only, the number of
resorption pits in TRPV5−/− was lower compared with wild-
type cultures (Fig. 7). The addition of 1,25(OH)2D3 to the
culture medium moderately increased the number of re-
sorption pits in both TRPV5+/+ and TRPV5−/− cultures.
Further increments of the 1,25(OH)2D3 concentration ulti-
mately reduced the number of resorption pits in cultures
from both genotypes. Osteoclast numbers were increased
by 1,25(OH)2D3 treatment in both TRPV5
+/+ and
TRPV5−/− mice (data not shown).
DISCUSSION
This study showed that treatment with the bone resorp-
tion inhibitor alendronate normalizes the reduced bone
thickness in TRPV5−/− mice. This clearly indicated that sig-
nificant bone resorption still occurs in these mice. In accor-
TABLE 1. SERUM AND URINE PARAMETERS DURING ALENDRONATE TREATMENT IN TRPV5+/+ AND TRPV5−/− MICE
TRPV5+/+ TRPV5−/−
Controls Alendronate Controls Alendronate
Serum
Ca2+ (mM) 2.36 ± 0.02 2.39 ± 0.03 2.49 ± 0.03* 2.54 ± 0.03*
PTH (pg/ml) 23 ± 8 14 ± 5 23 ± 5 122 ± 23*†
1,25(OH)2D3 (pM) 395 ± 19 489 ± 76 575 ± 70* 364 ± 42
†
Urine
Ca2+ excretion (mol/24 h) 9.3 ± 1.3 7.6 ± 0.6 102 ± 2* 85 ± 3*†
Diuresis (ml/24 h) 2.2 ± 0.5 2.0 ± 0.3 6.2 ± 0.1* 4.6 ± 0.3*†
Na+ excretion (mmol/24 h) 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.1
Li+ clearance (L/min) 15 ± 2 12 ± 1 17 ± 2 18 ± 2
pH 7.2 ± 0.2 7.3 ± 0.2 6.3 ± 0.3* 6.2 ± 0.2*
DPD (nM) 51 ± 12 29 ± 5 32 ± 4 15 ± 2†
Controls, mice treated with vehicle only; alendronate, mice treated for 10 wk with alendronate (2 mg/kg weekly). Data are presented as means ± SE.
* p < 0.05 vs. TRPV5+/+ controls.
† p < 0.05 vs. TRPV5−/− controls.
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dance, the expression of other ruffled border transporters
involved in osteoclast-mediated bone resorption (i.e., the
vacuolar H+-ATPase and ClC-7) remained unchanged in
TRPV5−/− mice. Interestingly, alendronate enhanced osteo-
clast TRPV5 expression, whereas the expression of the
Ca2+ transporters in kidney and intestine was not affected.
This indicated that alendronate specifically affects bone,
without altering renal or intestinal active Ca2+ (re)absorp-
tion. Taken together, these data suggest that the severely
impaired bone resorptive capacity that was shown in tibial
bone marrow cultures from TRPV5−/− mice(6) is rescued in
vivo. Because osteoclast numbers are increased in
TRPV5−/− mice and these osteoclasts retain 1,25(OH)2D3
responsiveness, the rescue mechanism might involve hyper-
vitaminosis D.
Alendronate treatment during 10 wk enhanced bone
thickness in TRPV5+/+ mice, which substantiates the thera-
peutic efficacy of this compound in mice. In TRPV5−/−
mice, alendronate normalized the significantly diminished
bone thickness and volume parameters compared with
TRPV5+/+ mice and reduced urinary excretion of the bone
resorption marker DPD. Furthermore, renal Ca2+ excretion
was diminished by alendronate in these mice, which is in
line with less Ca2+ being released from bone because of
TABLE 2. BONE MORPHOMETRY PARAMETERS DURING ALENDRONATE TREATMENT IN TRPV5+/+ AND TRPV5−/− MICE
TRPV5+/+ TRPV5−/−
Controls Alendronate Controls Alendronate
Femoral head
Tb.Th (m) 86 ± 2 85 ± 2 79 ± 2* 85 ± 2†
Tb.V. (mm3) 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1
BV/TV (%) 22 ± 1 31 ± 1* 21 ± 2 28 ± 2*†
Diaphysis
Ct.Th (m) 281 ± 3 308 ± 9* 223 ± 5* 268 ± 6†
Ct.V (mm3) 4.1 ± 0.2 4.4 ± 0.2 3.4 ± 0.2* 4.0 ± 0.3†
Ct.V/Dp.V (%) 56 ± 1 61 ± 1* 47 ± 1* 56 ± 1†
Bone morphometry parameters were determined by CT. Controls, mice treated with vehicle only; alendronate, mice treated for 10 wk with alendronate
(2 mg/kg weekly). In the femoral head, trabecular thickness (Tb.Th), trabecular volume (Tb.V), bone volume (BV), total bone marrow volume including
trabeculae (TV), and trabecular bone volume fraction (BV/TV) were determined. In the diaphysis, calculations were performed with regard to cortical
thickness (Ct.Th), cortical volume (Ct.V), total diaphyseal volume (Dp.V), and cortical bone volume fraction (Ct.V/Dp.V). Data are presented as means
± SE.
* p < 0.05 vs. TRPV5+/+ controls.
† p < 0.05 vs. TRPV5−/− controls.
FIG. 1. mRNA expression of epithelial Ca2+ channels in bone
during treatment with alendronate in TRPV5+/+ and TRPV5−/−
mice. The effect of alendronate treatment on mRNA expression
of the epithelial Ca2+ channels TRPV5 (A) and TRPV6 (B) in
bone was determined by real-time QPCR analysis, expressed as
the ratio of hypoxanthine-guanine phosphoribosyl transferase
(HPRT) and depicted as percentage of TRPV5+/+ controls. Con-
trols, mice treated with vehicle only; alendronate, mice treated for
10 wk with alendronate (2 mg/kg weekly). Data are presented as
means ± SE. *p < 0.05 vs. TRPV5+/+ controls. N  9 animals per
group.
FIG. 2. mRNA expression of the vacuolar H+-ATPase and the
Cl− channel ClC-7 in bone during treatment with alendronate in
TRPV5+/+ and TRPV5−/− mice. The effect of alendronate treat-
ment on mRNA expression of H+-ATPase (A) and ClC-7 (B) in
bone was determined by real-time QPCR analysis, expressed as
the ratio of hypoxanthine-guanine phosphoribosyl transferase
(HPRT) and depicted as percentage of TRPV5+/+ controls. Con-
trols, mice treated with vehicle only; alendronate, mice treated for
10 wk with alendronate (2 mg/kg weekly). Data are presented as
means ± SE. *p < 0.05 vs. TRPV5+/+ controls. #p < 0.05 vs.
TRPV5−/− controls. N  9 animals per group.
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inhibition of bone resorption. Previous studies showed that,
in bone, TRPV5 is exclusively expressed in the osteoclast
ruffled border and that osteoclasts from TRPV5−/− mice are
severely impaired in their bone resorptive capacity.(6) This
was exemplified by the near-absence of resorption pit for-
mation by osteoclasts derived from bone marrow cultures
of these knockout mice.(6) These data suggested that
TRPV5 is essential for proper osteoclastic bone resorption.
The significant bone-sparing response to alendronate, how-
ever, indicated that TRPV5−/− mice retain significant osteo-
clast-mediated bone resorptive capacity. This was substan-
tiated by the unaltered expression of the vacuolar H+-
ATPase and the chloride channel ClC-7 in bones from
TRPV5−/− mice, which are expressed along with TRPV5 at
the ruffled border of the osteoclast and are crucial to os-
teoclastic bone resorption.(19,20) Moreover, mutations in
these proteins have been shown to result in osteopetrosis,
characterized by increased BMD and decreased bone
length.(19,21,22,25) Osteoclasts from ClC-7–deficient mice
failed to form resorption pits, whereas osteoclast numbers
were increased, features that resemble osteoclast abnor-
malities in TRPV5−/− mice.(6,21,25–27) Thus, the severe mal-
function of TRPV5−/− osteoclasts would, theoretically, be
expected to lead to the clinical syndrome of osteopetrosis
instead of the observed reduced bone thickness in
TRPV5−/− mice.(6) Altogether, these data suggest that in
vivo compensatory mechanisms are involved which rescue
the impaired resorptive capacity of TRPV5-lacking osteo-
clasts.
In addition to TRPV5, TRPV6 is also expressed by os-
teoclasts, suggesting that TRPV6 could compensate for the
absence of TRPV5 in TRPV5−/− mice.(4,6) However, the
expression of TRPV6 in bone was unaltered in TRPV5−/−
mice and not affected by alendronate treatment. Impor-
tantly, TRPV5−/− mice showed significant hypervitaminosis
D, which was previously shown to counteract the renal Ca2+
leak by inducing intestinal hyperabsorption of Ca2+ medi-
ated by increased duodenal expression of the homologous
epithelial Ca2+ channel TRPV6 and calbindin-D9K.
(5,14) In
TRPV5/25–hydroxyvitamin-D3–1-hydroxylase double
knockout mice (TRPV5−/−/1-OHase−/−), in addition to
TRPV5 ablation, 1,25(OH)2D3 biosynthesis is impaired.
(14)
The compensatory Ca2+ hyperabsorption observed in
TRPV5−/− mice was absent in TRPV5−/−/1-OHase−/−
mice.(14) Importantly, the latter mice showed a distinct
bone phenotype including reduced bone length, along with
severe hypocalcemia and hyperparathyroidism. Whereas
physiological doses of 1,25(OH)2D3 inhibit PTH-induced
bone resorption, 1,25(OH)2D3 has been suggested to stimu-
late bone resorption by enhancing osteoclast formation
when present at supraphysiological levels.(28,29) Indeed,
both the number of mature osteoclasts and osteoclast pre-
cursors in bone marrow of TRPV5−/− mice were increased,
indicating an accelerated osteoclast differentiation pathway
in the presence of hypervitaminosis D in these mice.(6)
Taken together, these data suggest that the increased
1,25(OH)2D3 levels not only lead to Ca
2+ hyperabsorption
but might also rescue the impaired osteoclast function, con-
currently resulting in the maintenance of normocalcemia.
To address this hypothesis, TRPV5+/+ and TRPV5−/− bone
FIG. 4. mRNA expression of renal Ca2+ transporters during
treatment with alendronate in TRPV5+/+ and TRPV5−/− mice. The
effect of alendronate treatment on renal mRNA expression of the
epithelial Ca2+ channel TRPV5 (A) and the cytosolic Ca2+-
binding protein calbindin-D28K (CaBP28K; B) was determined by
real-time QPCR analysis, expressed as the ratio of hypoxanthine-
guanine phosphoribosyl transferase (HPRT) and depicted as per-
centage of TRPV5+/+ controls. Controls, mice treated with vehicle
only; alendronate, mice treated for 10 wk with alendronate (2
mg/kg weekly). Data are presented as means ± SE. *p < 0.05 vs.
TRPV5+/+ controls. N  9 animals per group.
FIG. 3. mRNA expression of the epithelial Ca2+ channel
TRPV5, the vacuolar H+-ATPase, and the Cl− channel ClC-7 in
cultured osteoclasts during treatment with alendronate. The effect
of alendronate application during 24 h on mRNA expression of
TRPV5 (A), H+-ATPase (B), and ClC-7 (C) in osteoclast cultures
was determined by real-time QPCR analysis, expressed as the
ratio of hypoxanthine-guanine phosphoribosyl transferase
(HPRT) and depicted as percentage of untreated control osteo-
clast cultures. Controls, osteoclasts treated with vehicle only; alen-
dronate, osteoclasts treated with 10−5 M alendronate. Data are
presented as means ± SE. N 5 osteoclast cultures per condition.
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marrow cultures were treated with different 1,25(OH)2D3
concentrations. These experiments substantiated that
TRPV5−/− osteoclasts form less resorption pits, whereas
their response to 1,25(OH)2D3 did not differ from
TRPV5+/+ osteoclasts. The fact that TRPV5−/− osteoclasts
retain the ability to enhance osteoclast numbers and resorp-
tion pit formation on stimulation by 1,25(OH)2D3 is in line
with the aforementioned hypothesis. Applying increasing
1,25(OH)2D3 concentrations in 10-fold increments eventu-
ally reduced the number of resorption pits and therefore
bone resorption capacity in both TRPV5+/+ and TRPV5−/−
bone marrow cultures. However, 1,25(OH)2D3 levels in
TRPV5−/− mice were significantly elevated but still re-
mained within the same order of magnitude than in the
wildtype animals, suggesting that this is not expected to
lead to a decreased bone resorption. Thus, because osteo-
clasts stay responsive to 1,25(OH)2D3 and osteoclastogen-
esis seems to be enhanced in these mice, the hypervitamin-
osis D could be involved in rescuing the osteoclast
phenotype in vivo.
Interestingly, TRPV5 expression in bone was increased
by alendronate treatment in TRPV5+/+ mice. However, the
expression of TRPV6 and the osteoclast markers ClC-7 and
the vacuolar H+-ATPase was unchanged, nor was the ex-
pression of Ca2+ transporters in kidney and intestine al-
tered. This indicated that osteoclast TRPV5 expression is
specifically upregulated when bone resorption is inhibited
by alendronate, substantiating that TRPV5 is important in
osteoclast function. In contrast, alendronate did enhance
ClC-7 and H+-ATPase expression in TRPV5−/− mice. Un-
like other bisphosphonates, which affect osteoclastogenesis
and induce apoptosis of mature osteoclasts, amino-
bisphosphonates such as alendronate are able to prevent
bone resorption without diminishing osteoclast numbers
FIG. 5. Protein abundance of renal Ca2+
transporters during treatment with alendro-
nate in TRPV5+/+ and TRPV5−/− mice. Rep-
resentative immunohistochemical images of
TRPV5 (A) and calbindin-D28K (CaBP28K;
B) staining in kidney cortex. Semiquantifica-
tion of renal TRPV5 (C) and calbindin-D28K
(D) protein abundance was performed by
computerized analysis of immunohistochem-
ical images. Data were calculated as inte-
grated optical density (IOD; arbitrary units)
and depicted as percentage of TRPV5+/+
controls. Controls, mice treated with vehicle
only; alendronate, mice treated for 10 wk
with alendronate (2 mg/kg weekly). Data are
presented as means ± SE. *p < 0.05 vs.
TRPV5+/+ controls. N  9 animals per
group.
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and have previously been shown to paradoxically increase
their quantity.(16,30–35) This effect was hypothesized to re-
flect a compensatory feedback mechanism caused by the
reduced release of Ca2+ from bone.(16,36) The upregulation
of CLC-7 and H+-ATPase, transporters known to be in-
volved in resorption pit acidification, observed in our study
coincided with a significant rise in serum PTH levels in
TRPV5−/− mice. Because the stimulatory effect of PTH on
osteoclast acidification as well as H+-ATPase and ClC-7 has
been previously shown,(16,34,37–41) the increased PTH levels
are likely responsible.
Whereas significantly increasing PTH levels, alendronate
treatment decreased the elevated serum 1,25(OH)2D3 lev-
els in TRPV5−/− mice. Although intriguing, these hormonal
changes are not readily explained. In addition, because the
hypervitaminosis D maintains the compensatory Ca2+ hy-
perabsorption in TRPV5−/− mice, alendronate treatment
would be expected to result in downregulation of the intes-
tinal Ca2+ transporters. However, the duodenal expression
of these transporters remained unchanged. Tentatively, the
high serum PTH or any of its downstream effects is in-
volved in maintaining the Ca2+ hyperabsorption. Whereas
the stimulatory effect of PTH on Ca2+ transporter expres-
sion and Ca2+ reabsorption has been shown in kidney and
PTH receptors are present in intestinal cells, the stimula-
tory effect on intestinal Ca2+ absorption is debated.(42–45)
These data indicate that the response to alendronate treat-
ment is different and more exaggerated in TRPV5−/− mice
compared with TRPV5+/+ mice. It is therefore likely that
alendronate-mediated inhibition of bone resorption seri-
ously challenges the fragile Ca2+ balance in these mice, ne-
cessitating at least the prolonged induction of PTH secre-
tion to ultimately maintain normocalcemia. However, the
exact mechanism explaining the adapted hormone status in
TRPV5−/− mice remains to be elucidated and warrants fur-
ther study.
Taken together, our data suggest that the impaired bone
resorption by TRPV5−/− osteoclasts determined in vitro is
rescued to a substantial degree in TRPV5−/− mice in vivo.
Possibly, the hypervitaminosis D, in addition to causing
Ca2+ hyperabsorption in intestine, is also involved in the
compensatory mechanism rescuing bone resorptive capac-
ity. The apparent interruption of this rescue mechanism by
alendronate treatment, whereas increasing bone thickness,
seems to critically jeopardize Ca2+ homeostasis, leading to
several compensatory effects including increased PTH se-
cretion. However, these data do not yet explain the bone
phenotype in TRPV5−/− mice.(5,14) In the presence of an
intrinsic defect of bone resorption, reduced bone formation
is likely involved. Because bone formation and resorption
were shown to be closely related processes, which show a
considerable amount of cross-talk, an altered bone forma-
tion–resorption coupling might contribute to the reduced
bone thickness.(46–49) In addition, the primary renal Ca2+
wasting causes a negative Ca2+ balance, and therefore, less
Ca2+ may be available for bone formation.(5) Of note,
1,25(OH)2D3 treatment of murine osteoblasts was previ-
ously shown to inhibit the development of a mature osteo-
blast phenotype and matrix mineralization.(50) Further
studies are needed to unravel the exact relationship be-
tween TRPV5 ablation, osteoclast and osteoblast function,
serum 1,25(OH)2D3 and PTH levels, and the reduced bone
thickness in TRPV5−/− mice.
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